A clinical trial using an anti-NKG2D antagonist antibody in inflammatory bowel diseases has provided the proof of concept that the NKG2D-NKG2DL interaction is a valid therapeutic target in human inflammatory diseases (42). The gene discussed is KLRK1; the disease is inflammatory bowel disease.